Tech Company M&A Transactions
Calistoga Pharmaceuticals Acquisition
On 2/22/2011, Calistoga Pharmaceuticals was acquired by Gilead Sciences. Gilead Sciences said the transaction price was $375 million.
Transaction Overview
Company Name
Acquired By
Announced On
2/22/2011
Transaction Type
M&A
Amount
$375,000,000
M&A Terms
Calistoga could earn up to an additional $225 million if certain milestones are achieved.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
2101 - 4th Ave. 1960
Seattle, WA 98121
USA
Seattle, WA 98121
USA
Phone
Website
Email Address
Overview
Calistoga Pharmaceuticals, is developing a drug candidate acquired from Icos that has potential to treat various forms of cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carol Gallagher
Chief Financial Officer
Andrew Guggenhime
Chief Medical Officer
Albert Yu
VP - R & D
Langdon Miller
Browse more venture capital transactions:
Prev: 2/22/2011: Cardeas Pharma venture capital transaction
Next: 2/22/2011: Correx venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs